Stemline Therapeutics Announces SL-701 and SL-801 Clinical Data to be Featured, Including an Oral Presentation, at Upcoming ESMO 2018 Congress

On October 16, 2018 Stemline Therapeutics, Inc. (Nasdaq: STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, reported that clinical data from its SL-701 and SL-801 trials have been selected for presentation, including an oral presentation, at the upcoming European Society of Medical Oncology (ESMO) (Free ESMO Whitepaper) Annual Congress 2018 to be held from October 19-23, in Munich, Germany (Press release, Stemline Therapeutics, OCT 16, 2018, View Source [SID1234529928]). The details of the data presentations are outlined below.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Results of Phase II Trial Of SL-701, a Novel Immunotherapy Targeting IL-13Ra2, Epha2, and Survivin, in Adults with Second-Line Recurrent Glioblastoma (GBM)

Type: Oral Presentation
Session: Proffered Paper session – CNS tumours
Presentation Number: 373O
Date: Friday, October 19, 2018
Lecture Time: 16:39 – 16:51 CEST (10:39 AM EDT)
Speaker: David Peereboom, MD; Cleveland Clinic
Interim Results from a Phase 1 Trial of SL-801, a Novel XPO-1 Inhibitor, in Patients with Advanced Solid Tumors

Type: Poster Presentation
Session: Poster display session: Breast cancer – early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours – prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Presentation Number: 428P
Date: Monday, October 22, 2018
Time: 12:45 – 13:45 CEST (6:45 – 7:45 AM EDT)
Speaker: Todd M. Bauer, MD; Tennessee Oncology
Abstracts are currently available on the ESMO (Free ESMO Whitepaper) congress website (www.esmo.org). Following each presentation at the conference, the data presented will be available on Stemline’s website (www.stemline.com) under the Scientific Presentations tab.